Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04506606 · ClinicalTrials.gov registry record · NA
Cardiac Rehab Effects in HFpEF
A NA study of Heart Failure With Preserved Ejection Fraction, sponsored by VA Office of Research and Development.
- Active
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04506606: Active NA study of Heart Failure With Preserved Ejection Fraction, sponsored by VA Office of Research and Development.
NCT04506606 is a NA study of Heart Failure With Preserved Ejection Fraction that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 45 participants, below the 2,287-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04506606, a NA study of Heart Failure With Preserved Ejection Fraction, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This research in Veterans with heart failure with preserved ejection fraction (HFpEF) will provide new information on the mechanisms determining the patients' exercise intolerance and the efficacy of regular physical activity to improve this shortcoming by alleviating the patients' neurocirculatory abnormalities. Specifically, the investigators will focus on the role of nerves originating in working limb muscles in determining the patients' exercise intolerance and compromised fatigue resistance before and after a chronic exercise intervention. By focusing on a specific mechanism, this project will evaluate the validity of exercise as an alternative treatment strategy with the overall purpose of improving the quality of life of Veterans with HFpEF.
Primary Outcome
Quantifying femoral blood flow during exercise with and without afferent blockade
Conditions Studied
Interventions
- PROCEDURE Afferent block
Study Locations (1)
Utah
- VA Salt Lake City Health Care System, Salt Lake City, UT - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-05-02 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What the registry record for NCT04506606 still lists
NCT04506606 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 2,287-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which Afferent block is the first listed.
NCT04506606 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT04506606 about?
NCT04506606 is a clinical study titled "Cardiac Rehab Effects in HFpEF". This research in Veterans with heart failure with preserved ejection fraction (HFpEF) will provide new information on the mechanisms determining the patients' exercise intolerance and the efficacy of regular physical activity to improve this shortcoming by alleviating the patients' neurocirculatory ...
What is the current status of trial NCT04506606?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2022-05-02. Estimated completion is 2026-09-30.
What conditions does trial NCT04506606 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction.
What interventions are being tested in trial NCT04506606?
The interventions under investigation include: Afferent block (PROCEDURE).
Who is sponsoring clinical trial NCT04506606?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04506606 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04506606's enrollment target sits among peer trials
45 28th of 42 higher than 15 of 42 other Heart Failure With Preserved Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · NA
-
Ketogenic Diet vs Mixed Diet in Patients With Heart Failure
RECRUITING · NA
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
-
Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
-
Transitions of Care Clinic (TOCC)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI